Patents by Inventor Steven T. Miller

Steven T. Miller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RNAi-Mediated Inhibition of Tumor Necrosis Factor Alpha-Related Conditions
    Publication number: 20190032061
    Abstract: RNA interference is provided for inhibition of tumor necrosis factor ? (TNF?) by silencing TNF? cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNF? converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNF? targets, in particular, is useful for treating patients having a TNF?-related condition or at risk of developing a TNF?-related condition such as the ocular conditions dry eye, allergic conjunctivitis, or ocular inflammation, or such as dermatitis, rhinitis, or asthma, for example.
    Type: Application
    Filed: October 11, 2018
    Publication date: January 31, 2019
    Inventors: John M. Yanni, Jon E. Chatterton, Diane Michelle Senchyna, Daniel A. Gamache, Steven T. Miller
  • RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of CAMP-related ocular disorders
    Patent number: 9765340
    Abstract: RNA interference is provided for inhibition of phosphodiesterase type 4 mRNA expression for treating patients with a cAMP-related ocular disorder. Phosphodiesterase type 4 mRNA targets include mRNA for 4A, 4B, 4C, and 4D phosphodiesterase isoforms.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: September 19, 2017
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: John M. Yanni, Jon E. Chatterton, Daniel A. Gamache, Steven T. Miller
  • RNAi-mediated inhibition of histamine receptor H1-related conditions
    Patent number: 9745585
    Abstract: RNA interference is provided for inhibition of histamine receptor H1 mRNA expression, in particular, for treating patients having an HRH1-related condition or at risk of developing an HRH1-related condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, or allergy.
    Type: Grant
    Filed: November 2, 2015
    Date of Patent: August 29, 2017
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: John M. Yanni, Jon E. Chatterton, Daniel A. Gamache, Steven T. Miller
  • RNAi-Mediated Inhibition of Phosphodiesterase Type 4 for Treatment of CAMP-Related Ocular Disorders
    Publication number: 20170051291
    Abstract: RNA interference is provided for inhibition of phosphodiesterase type 4 mRNA expression for treating patients with a cAMP-related ocular disorder. Phosphodiesterase type 4 mRNA targets include mRNA for 4A, 4B, 4C, and 4D phosphodiesterase isoforms.
    Type: Application
    Filed: September 2, 2016
    Publication date: February 23, 2017
    Inventors: John M. Yanni, Jon E. Chatterton, Daniel A. Gamache, Steven T. Miller
  • RNAi-Mediated Inhibition of Tumor Necrosis Factor Alpha-Related Conditions
    Publication number: 20160369283
    Abstract: RNA interference is provided for inhibition of tumor necrosis factor ? (TNF?) by silencing TNF? cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNF? converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNF? targets, in particular, is useful for treating patients having a TNF?-related condition or at risk of developing a TNF?-related condition such as the ocular conditions dry eye, allergic conjunctivitis, or ocular inflammation, or such as dermatitis, rhinitis, or asthma, for example.
    Type: Application
    Filed: September 2, 2016
    Publication date: December 22, 2016
    Inventors: John M. Yanni, Jon E. Chatterton, Diane Michelle Senchyna, Daniel A. Gamache, Steven T. Miller
  • RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders
    Patent number: 9453220
    Abstract: RNA interference is provided for inhibition of phosphodiesterase type 4 mRNA expression for treating patients with a cAMP-related ocular disorder. Phosphodiesterase type 4 mRNA targets include mRNA for 4A, 4B, 4C, and 4D phosphodiesterase isoforms.
    Type: Grant
    Filed: January 23, 2014
    Date of Patent: September 27, 2016
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: John M. Yanni, John E. Chatterton, Daniel A. Gamache, Steven T. Miller
  • RNAi-mediated inhibition of tumor necrosis factor ?-related conditions
    Patent number: 9447419
    Abstract: RNA interference is provided for inhibition of tumor necrosis factor ? (TNF?) by silencing TNF? cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNF? converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNF? targets, in particular, is useful for treating patients having a TNF?-related condition or at risk of developing a TNF?-related condition such as the ocular conditions dry eye, allergic conjunctivitis, or ocular inflammation, or such as dermatitis, rhinitis, or asthma, for example.
    Type: Grant
    Filed: April 3, 2014
    Date of Patent: September 20, 2016
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: John M. Yanni, Jon E. Chatterton, Diane Michelle Senchyna, Daniel A. Gamache, Steven T. Miller
  • RNAi-MEDIATED INHIBITION OF SPLEEN TYROSINE KINASE-RELATED INFLAMMATORY CONDITIONS
    Publication number: 20160257963
    Abstract: RNA interference is provided for inhibition of spleen tyrosine kinase (Syk) mRNA expression, in particular, for treating patients having a Syk-related inflammatory condition or at risk of developing a Syk-related inflammatory condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, allergy, or mast-cell disease.
    Type: Application
    Filed: May 17, 2016
    Publication date: September 8, 2016
    Inventors: John M. Yanni, Jon E. Chatterton, Daniel A. Gamache, Steven T. Miller
  • RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions
    Patent number: 9371529
    Abstract: RNA interference is provided for inhibition of spleen tyrosine kinase (Syk) mRNA expression, in particular, for treating patients having a Syk-related inflammatory condition or at risk of developing a Syk-related inflammatory condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, allergy, or mast-cell disease.
    Type: Grant
    Filed: May 5, 2014
    Date of Patent: June 21, 2016
    Assignee: Arrowhead Research Corporation
    Inventors: John M. Yanni, Jon E. Chatterton, Daniel A. Gamache, Steven T. Miller
  • RNAi-MEDIATED INHIBITION OF HISTAMINE RECEPTOR H1-RELATED CONDITIONS
    Publication number: 20160053270
    Abstract: RNA interference is provided for inhibition of histamine receptor H1 mRNA expression, in particular, for treating patients having an HRH1-related condition or at risk of developing an HRH1-related condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, or allergy.
    Type: Application
    Filed: November 2, 2015
    Publication date: February 25, 2016
    Inventors: John M. Yanni, Jon E. Chatterton, Daniel A. Gamache, Steven T. Miller
  • RNAi-mediated inhibition of histamine receptor H1-related conditions
    Patent number: 9206428
    Abstract: RNA interference is provided for inhibition of histamine receptor H1 mRNA expression, in particular, for treating patients having an HRH1-related condition or at risk of developing an HRH1-related condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, or allergy.
    Type: Grant
    Filed: November 22, 2013
    Date of Patent: December 8, 2015
    Assignee: Arrowhead Research Corporation
    Inventors: John M. Yanni, Jon E. Chatterton, Daniel A. Gamache, Steven T. Miller
  • RNAi-MEDIATED INHIBITION OF SPLEEN TYROSINE KINASE-RELATED INFLAMMATORY CONDITIONS
    Publication number: 20140357695
    Abstract: RNA interference is provided for inhibition of spleen tyrosine kinase (Syk) mRNA expression, in particular, for treating patients having a Syk-related inflammatory condition or at risk of developing a Syk-related inflammatory condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, allergy, or mast-cell disease.
    Type: Application
    Filed: May 5, 2014
    Publication date: December 4, 2014
    Applicant: ALCON RESEARCH, LTD.
    Inventors: John M. Yanni, Jon E. Chatterton, Daniel A. Gamache, Steven T. Miller
  • RNAi-MEDIATED INHIBITION OF TUMOR NECROSIS FACTOR ALPHA-RELATED CONDITIONS
    Publication number: 20140357694
    Abstract: RNA interference is provided for inhibition of tumor necrosis factor ? (TNF?) by silencing TNF? cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNF? converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNF? targets, in particular, is useful for treating patients having a TNF?-related condition or at risk of developing a TNF?-related condition such as the ocular conditions dry eye, allergic conjunctivitis, or ocular inflammation, or such as dermatitis, rhinitis, or asthma, for example.
    Type: Application
    Filed: April 3, 2014
    Publication date: December 4, 2014
    Applicant: ALCON RESEARCH, LTD.
    Inventors: John M. Yanni, Jon E. Chatterton, Diane Michelle Senchyna, Daniel A. Gamache, Steven T. Miller
  • RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions
    Patent number: 8865671
    Abstract: RNA interference is provided for inhibition of spleen tyrosine kinase (Syk) mRNA expression, in particular, for treating patients having a Syk-related inflammatory condition or at risk of developing a Syk-related inflammatory condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, allergy, or mast-cell disease.
    Type: Grant
    Filed: June 30, 2011
    Date of Patent: October 21, 2014
    Assignee: Alcon Research, Ltd.
    Inventors: John M. Yanni, Jon E. Chatterton, Daniel A. Gamache, Steven T. Miller
  • RNAi-MEDIATED INHIBITION OF PHOSPHODIESTERASE TYPE 4 FOR TREATMENT OF cAMP-RELATED OCULAR DISORDERS
    Publication number: 20140171487
    Abstract: RNA interference is provided for inhibition of phosphodiesterase type 4 mRNA expression for treating patients with a cAMP-related ocular disorder. Phosphodiesterase type 4 mRNA targets include mRNA for 4A, 4B, 4C, and 4D phosphodiesterase isoforms.
    Type: Application
    Filed: January 23, 2014
    Publication date: June 19, 2014
    Applicant: Alcon Research, Ltd.
    Inventors: John M. Yanni, John E. Chatterton, Daniel A. Gamache, Steven T. Miller
  • RNAi-Mediated Inhibition of Histamine Receptor H1-Related Conditions
    Publication number: 20140088172
    Abstract: RNA interference is provided for inhibition of histamine receptor H1 mRNA expression, in particular, for treating patients having an HRH1-related condition or at risk of developing an HRH1-related condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, or allergy.
    Type: Application
    Filed: November 22, 2013
    Publication date: March 27, 2014
    Applicant: Alcon Research, Ltd.
    Inventors: John M. Yanni, Jon E. Chatterton, Daniel A. Gamache, Steven T. Miller
  • RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders
    Patent number: 8673873
    Abstract: RNA interference is provided for inhibition of phosphodiesterase type 4 mRNA expression for treating patients with a cAMP-related ocular disorder. Phosphodiesterase type 4 mRNA targets include mRNA for 4A, 4B, 4C, and 4D phosphodiesterase isoforms.
    Type: Grant
    Filed: October 16, 2009
    Date of Patent: March 18, 2014
    Assignee: Alcon Research, Ltd.
    Inventors: John M. Yanni, Jon E. Chatterton, Daniel A. Gamache, Steven T. Miller
  • RNAi-mediated inhibition of histamine receptor H1-related conditions
    Patent number: 8618278
    Abstract: RNA interference is provided for inhibition of histamine receptor H1 mRNA expression, in particular, for treating patients having an HRH1-related condition or at risk of developing an HRH1-related condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, or allergy.
    Type: Grant
    Filed: June 11, 2012
    Date of Patent: December 31, 2013
    Assignee: Alcon Research, Ltd.
    Inventors: John M. Yanni, Jon E. Chatterton, Daniel A. Gamache, Steven T. Miller
  • RNAi-MEDIATED INHIBITION OF TUMOR NECROSIS FACTOR ALPHA-RELATED CONDITIONS
    Publication number: 20130338213
    Abstract: RNA interference is provided for inhibition of tumor necrosis factor ? (TNF?) by silencing TNF? cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNF? converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNF? targets, in particular, is useful for treating patients having a TNF?-related condition or at risk of developing a TNF?-related condition such as the ocular conditions dry eye, allergic conjunctivitis, or ocular inflammation, or such as dermatitis, rhinitis, or asthma, for example.
    Type: Application
    Filed: August 22, 2013
    Publication date: December 19, 2013
    Applicant: Alcon Research, Ltd.
    Inventors: John M. Yanni, Jon E. Chatterton, Diane Michelle Senchyna, Daniel A. Gamache, Steven T. Miller
  • RNAi-mediated inhibition of tumor necrosis factor ?-related conditions
    Patent number: 8541389
    Abstract: RNA interference is provided for inhibition of tumor necrosis factor ? (TNF?) by silencing TNF? cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNF? converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNF? targets, in particular, is useful for treating patients having a TNF?-related condition or at risk of developing a TNF?-related condition such as the ocular conditions dry eye, allergic conjunctivitis, or ocular inflammation, or such as dermatitis, rhinitis, or asthma, for example.
    Type: Grant
    Filed: February 25, 2011
    Date of Patent: September 24, 2013
    Assignee: Alcon Research, Ltd.
    Inventors: John M. Yanni, Jon E. Chatterton, Diane Michelle Senchyna, Daniel A. Gamache, Steven T. Miller